189 related articles for article (PubMed ID: 10078713)
41. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
Erkinjuntti T; Kurz A; Gauthier S; Bullock R; Lilienfeld S; Damaraju CV
Lancet; 2002 Apr; 359(9314):1283-90. PubMed ID: 11965273
[TBL] [Abstract][Full Text] [Related]
42. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
[TBL] [Abstract][Full Text] [Related]
43. Effect of food on the absorption of eptastigmine.
Bjornsson TD; Troetel WM; Imbimbo BP
Eur J Clin Pharmacol; 1998 May; 54(3):243-7. PubMed ID: 9681667
[TBL] [Abstract][Full Text] [Related]
44. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
[TBL] [Abstract][Full Text] [Related]
46. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
Kumar V; Anand R; Messina J; Hartman R; Veach J
Eur J Neurol; 2000 Mar; 7(2):159-69. PubMed ID: 10809936
[TBL] [Abstract][Full Text] [Related]
47. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
48. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Dubois B; Tolosa E; Katzenschlager R; Emre M; Lees AJ; Schumann G; Pourcher E; Gray J; Thomas G; Swartz J; Hsu T; Moline ML
Mov Disord; 2012 Sep; 27(10):1230-8. PubMed ID: 22915447
[TBL] [Abstract][Full Text] [Related]
49. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
[TBL] [Abstract][Full Text] [Related]
50. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Nordberg A; Svensson AL
Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
[TBL] [Abstract][Full Text] [Related]
51. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials.
Román GC; Wilkinson DG; Doody RS; Black SE; Salloway SP; Schindler RJ
Dement Geriatr Cogn Disord; 2005; 20(6):338-44. PubMed ID: 16192723
[TBL] [Abstract][Full Text] [Related]
52. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
Gold M; Alderton C; Zvartau-Hind M; Egginton S; Saunders AM; Irizarry M; Craft S; Landreth G; Linnamägi U; Sawchak S
Dement Geriatr Cogn Disord; 2010; 30(2):131-46. PubMed ID: 20733306
[TBL] [Abstract][Full Text] [Related]
53. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial.
Akhondzadeh S; Noroozian M; Mohammadi M; Ohadinia S; Jamshidi AH; Khani M
J Clin Pharm Ther; 2003 Feb; 28(1):53-9. PubMed ID: 12605619
[TBL] [Abstract][Full Text] [Related]
54. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
[TBL] [Abstract][Full Text] [Related]
55. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
Forette F; Anand R; Gharabawi G
Eur J Neurol; 1999 Jul; 6(4):423-9. PubMed ID: 10362894
[TBL] [Abstract][Full Text] [Related]
56. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
Rockwood K; Fay S; Song X; MacKnight C; Gorman M;
CMAJ; 2006 Apr; 174(8):1099-105. PubMed ID: 16554498
[TBL] [Abstract][Full Text] [Related]
57. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type.
Möller H-J ; Hampel H; Hegerl U; Schmitt W; Walter K
Pharmacopsychiatry; 1999 May; 32(3):99-106. PubMed ID: 10463377
[TBL] [Abstract][Full Text] [Related]
58. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease.
Maher-Edwards G; Zvartau-Hind M; Hunter AJ; Gold M; Hopton G; Jacobs G; Davy M; Williams P
Curr Alzheimer Res; 2010 Aug; 7(5):374-85. PubMed ID: 20043816
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
Black S; Román GC; Geldmacher DS; Salloway S; Hecker J; Burns A; Perdomo C; Kumar D; Pratt R;
Stroke; 2003 Oct; 34(10):2323-30. PubMed ID: 12970516
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
